) The University of California San Francisco (UCSF) will participate in the c l inical trials of North American Brain Consortium (NABTC). Member institutions will include UCSF, the University of Wisconsin, the University of Pittsburgh, Dana Farber Cancer Center, M.D. Anderson Cancer Center, the University of Texas Southwestern, the University of Michigan, and the University of Texas San Antonio. UCSF will be the lead institution and Dr. Prados, the project leader for the NABTC. The focus of this grant will be to continue to initiate and carefully analyze data generated from investigational Phase 1/11 trials in adult patients with malignant gliomas. Patients at UCSF will be evaluated and treated by a multi-disciplinary team composed of Neuro-Oncologists, Medical Oncologists, Neurosurgeons, Radiation Oncologists, Neuropathologists, Neuroradiologists, and Clinical Research Nurses, with the date monitored and evaluated by dedicated data managers. Tissue obtained from patients at the time of surgery will be collected and stored in a tissue bank for on-going and future laboratory based studies, as well as clinical-laboratory correlations as they develop over the period of this grant. The effort will be multi-institutional for the purpose of increasing patient accrual for rapid study determations, to share human tissue specimens between member institutions with specialized interest or expertise, but most importantly to cooperate in creative efforts in order to maintain the highest level of interest in laboratory based translational clinical research. The UCSF institutional and NABTC multi-institutional effort will be intimately linked with the on-going interests, needs, and support of the cancer therapy 'II be intimately linked with the on-going interests, needs, and support of the cancer therapy evaluation program (CTEP) and the radiation research program (RRP) of the division of cancer treatment. The overall goal of this program is to more effectively treat patients with malignant gliomas with the purpose of increasing duration and quality of survival.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-CRB-K (O1))
Program Officer
Wu, Roy S
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
Schools of Medicine
San Francisco
United States
Zip Code
Taylor, Jennie W; Parikh, Mili; Phillips, Joanna J et al. (2018) Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma. J Neurooncol 140:477-483
Vivanco, Igor; Robins, H Ian; Rohle, Daniel et al. (2012) Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov 2:458-71
Norden, Andrew D; Raizer, Jeffrey J; Abrey, Lauren E et al. (2010) Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol 96:211-7
Raizer, Jeffrey J; Abrey, Lauren E; Lassman, Andrew B et al. (2010) A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol 12:95-103
Iwamoto, Fabio M; Lamborn, Kathleen R; Robins, H Ian et al. (2010) Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol 12:855-61
Raizer, Jeffrey J; Abrey, Lauren E; Lassman, Andrew B et al. (2010) A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol 12:87-94
Guo, Deliang; Prins, Robert M; Dang, Julie et al. (2009) EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal 2:ra82
Chang, Susan M; Lamborn, Kathleen R; Kuhn, John G et al. (2008) Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. Neuro Oncol 10:631-42
Lamborn, Kathleen R; Yung, W K Alfred; Chang, Susan M et al. (2008) Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 10:162-70
Prados, Michael D; Yung, W K A; Wen, Patrick Y et al. (2008) Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. Cancer Chemother Pharmacol 61:1059-67

Showing the most recent 10 out of 23 publications